Hims & Hers Health (HIMS)
International Stocks
Buy
Analyzes recent price movements in Hims & Hers Health stock and the company's market performance.
Jeremy Lefebvre38d
* Does not constitute investment advice
Yükleniyor...
Yükleniyor...
How recommendation distribution changed over time
Covered by 5 analysts
Mixed views among analysts
Last evaluation 38+ days ago - stale data
Both buy and sell recommendations exist
Decreasing interest recently
Chronological view of analyst recommendations for this asset
Analyzes recent price movements in Hims & Hers Health stock and the company's market performance.
Financial EducationThe speaker analyzes speculative movements in the stock and potential technical scenarios.
Meet KevinThe speaker examines the warning letter sent to the company regarding unauthorized compounding of GLP-1 drugs and marketing claims, along with regulatory risks.
CNBC TelevisionThe speaker discusses legal proceedings involving compounding firms, raw material sources, and intellectual property rights.
CNBC TelevisionThe speaker discusses the legal challenges involving Novo Nordisk and the resulting uncertainty surrounding the company's future financial projections and stock stability.
Financial EducationThe legal status of the weight-loss drug launched by the company, potential regulatory sanctions, and "unapproved drug" risks are detailed by a former FDA official.
CNBC TelevisionThe speaker evaluates the company's entry strategy into the Canadian market, the LivWell acquisition, and plans for the rollout of generic weight loss drugs.
CNBC TelevisionThe speaker evaluates the rising correlation risk in stocks like Hims & Hers during market weakness and potential negative outcomes of retail investor behaviors.
CNBC TelevisionAnalyzes recent price movements in Hims & Hers Health stock and the company's market performance.
* Does not constitute investment advice
The speaker analyzes speculative movements in the stock and potential technical scenarios.
* Does not constitute investment advice
The speaker examines the warning letter sent to the company regarding unauthorized compounding of GLP-1 drugs and marketing claims, along with regulatory risks.
* Does not constitute investment advice
The speaker discusses legal proceedings involving compounding firms, raw material sources, and intellectual property rights.
* Does not constitute investment advice
The speaker discusses the legal challenges involving Novo Nordisk and the resulting uncertainty surrounding the company's future financial projections and stock stability.
* Does not constitute investment advice
The legal status of the weight-loss drug launched by the company, potential regulatory sanctions, and "unapproved drug" risks are detailed by a former FDA official.
* Does not constitute investment advice
The speaker evaluates the company's entry strategy into the Canadian market, the LivWell acquisition, and plans for the rollout of generic weight loss drugs.
* Does not constitute investment advice
The speaker evaluates the rising correlation risk in stocks like Hims & Hers during market weakness and potential negative outcomes of retail investor behaviors.
* Does not constitute investment advice